PDL 2024
South Dakota Medicaid joined the Sovereign States Drug Consortium effective January 1, 2023.
If a drug or class is not listed, it is not subject to the PDL. Any drug not listed in one classes below is non-preferred.
| Therapeutic Category | Preferred Drugs |
| ADHD NON-STIMULANT | NON-STIMULANT ORAL AGENTS (e.g., atomoxetine, clonidine, etc) QELBREE |
| ANTICONVULSANTS | ANTISEIZURE AGENTS (e.g., carbamazepine, lamotrigine, phenytoin, topiramate, etc) DIAZEPAM RECTAL GEL EPIDIOLEX SOLUTION NAYZILAM NASAL SPRAY VALTOCO NASAL SPRAY |
| ANTIDIABETICS GLP-1 RECEPTOR AGONISTS | OZEMPIC RYBELSUS TRULICITY |
| ANTIRETROVIRALS | BIKTARVY DESCOVY GENVOYA |
| CGM - CONTINUOUS GLUCOSE MONITORING | DEXCOM G6 DEXCOM G7 FREESTYLE LIBRE 14 DAY FREESTYLE LIBRE 2 FREESTYLE LIBRE 3 GUARDIAN 4 GUARDIAN CONNECT GUARDIAN LINK 3 GUARDIAN SENSOR 3 |
| CNS ANTIPSYCHOTICS | ORAL AGENTS (e.g., aripiprazole, clozapine, olanzapine, paliperidone, risperidone, etc) ABILIFY ASIMTUFI ABILIFY MAINTENA ARISTADA ARISTADA INITIO INVEGA SUSTENNA INVEGA TRINZA INVEGA HAFYERA VRAYLAR |
| CARDIOVASCULAR – ARB-NEPRILYSIN INHIBITOR | ENTRESTO |
| CYTOKINE MODULATORS | ENBREL ENBREL MINI ENBREL SURECLICK HUMIRA HUMIRA Pen HUMIRA Pediatric Crohns HUMIRA Pen-PS/UV Starter SKYRIZIA SKYRIZI Pen TALTZ |
| DERM-ATOPIC DERMATITIS MONOCLONAL ANTIBODY - ANTI-IL, ANTI IGE | TOPICAL AGENTS (e.g., pimecrolimus cream, tacrolimus ointment, topical corticosterioid, Eucrisa, etc) DUPIXENT |
| GI PANCREATIC ENZYMES | ZENPEP |
| GROWTH HORMONES | GENOTROPIN GENOTROPIN MINIQUICK NORDITROPIN FLEXPRO |
| HEPATITIS C | SOFOSBUVIR/VELPATASVIR TAB MAVYRET |
| HYPOGLYCEMIA | BAQSIMI |
| MIGRAINE - CGRP INHIBITORS | AIMOVIG EMGALITY |
| MIGRAINE TREATMENT | TRIPTANS (e.g., almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, etc) UBRELVY |
| MOVEMENT DISORDER | AUSTEDO AUSTEDO XR INGREZZA |
| RESPIRATORY - ADRENERGIC COMBINATIONS | COMBIVENT RESPIMAT STIOLTO RESPIMAT |
| RESPIRATORY - ANTICHOLINERGICS | SPIRIVA RESPIMAT |